Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study

Lancet

Volumn 353, Issue 9156, 1999, Pages 863-868

  Ledergerber, Bruno ^a,h   Egger, Matthias ^b   Opravil, Milos ^a   Telenti, Amalio ^c   Hirschel, Bernard ^d   Battegay, Manuel ^e   Vernazza, Pietro ^f   Sudre, Philippe ^c   Flepp, Markus ^a   Furrer, Hansjakob ^g   Francioli, Patrick ^c   Weber, Rainer ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g UNIVERSITY OF BERN   (Switzerland)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REBOUND; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0033550965     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)01122-8     Document Type: Article

References (28)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-39.
3. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection. JAMA 1998; 280: 35-41.
4. Fätkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11: F113-16.
5. Fleming TR, Prentice RL, Pepe MS, Glidden D. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Stat Med 1994; 13: 955-68.
6. Babiker A. Can HIV-1 RNA viral load be used as a surrogate for clinical endpoints in HIV disease? Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection, Hamburg. October 11-15, 1997; 207 (abstr).
7. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
8. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315: 1194-99.
9. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725-30.
10. Ledergerber B, von Overbeck J, Egger M, Lüthy R. The Swiss HIV cohort study: rationale, organization and selected baseline characteristics. Soz Präventivmed 1994; 39: 387-94.
11. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41: 1-19.
12. Montaner JSG, Reiss P, Cooper DA, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. JAMA 1998; 279: 930-37.
13. Kaufmann D, Pantaleo G, Sudre P, Telenti A, for the Swiss HIV Cohort Study. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998; 351: 723-24.
14. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450-54.
15. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997; 11: 1731-38.
16. Casado JL, PerezElias MJ, Antela A, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998; 12: F131-35.
17. Monforte AD, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998; 12: 1631-37.
18. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998; 12: 1261-67.
19. Lorenzi P, Opravil M, Hirschel B. Impact of drug resistance mutations on virologie response to salvage therapy. AIDS 1999; 13: F17-21.
20. Green SB, Byar DP. Using observational data from registries to compare treatments: the fallacy of omnimetrics. Stat Med 1984; 3: 361-73.
21. Feinstein A. The role of observational studies in the evaluation of therapy. Stat Med 1984; 3: 341-45.
22. Perry CM, Noble S. Saquinavir soft-gel capsule formulation: a review of its use in patients with HIV infection. Drugs 1998; 55: 461-86.
23. Hirschel B, Francioli P. Progress and problems in the fight against AIDS. N Engl J Med 1998; 338: 906-08.
24. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1881-83.
25. Ho DD. Viral counts count in HIV infection. Science 1996; 272: 1124-25.
26. Levy JA. Caution: should we be treating HIV infection early? Lancet 1998; 352: 982-83.
27. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998; 280: 78-86.
28. Gazzard BG, Moyle G, on behalf of the BHIVA Guidelines Writing Committee. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352: 314-16.